84 related articles for article (PubMed ID: 10761452)
1. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas.
Chang CC; Liu YC; Cleveland RP; Perkins SL
Am J Clin Pathol; 2000 Apr; 113(4):512-8. PubMed ID: 10761452
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
3. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Gualco G; Weiss LM; Barber GN; Bacchi CE
Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
[TBL] [Abstract][Full Text] [Related]
7. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
[TBL] [Abstract][Full Text] [Related]
8. An immunophenotypic and molecular study of primary large B-cell lymphoma of bone.
Huebner-Chan D; Fernandes B; Yang G; Lim MS
Mod Pathol; 2001 Oct; 14(10):1000-7. PubMed ID: 11598170
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
Xu Y; McKenna RW; Molberg KH; Kroft SH
Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
[TBL] [Abstract][Full Text] [Related]
11. Large B-cell lymphoma with Hodgkin's features.
García JF; Mollejo M; Fraga M; Forteza J; Muniesa JA; Pérez-Guillermo M; Pérez-Seoane C; Rivera T; Ortega P; Piris MA
Histopathology; 2005 Jul; 47(1):101-10. PubMed ID: 15982329
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of c-Myc and p53 as a marker of survival time.
Vollmer RT
Am J Clin Pathol; 2000 Dec; 114(6):983-5. PubMed ID: 11338487
[No Abstract] [Full Text] [Related]
13. Centroblastic and centroblastic/centrocytic lymphoma associated with a prominent epithelioid granulomatous response: a clinicopathologic study of 50 cases.
Kojima M; Nakamura S; Ichimura K; Suzuki R; Kagami Y; Kondo E; Motoori T; Hosomura Y; Oyama T; Itoh H; Ban S; Yoshida K; Ohno Y; Shimizu K; Masawa N; Sugihara S
Mod Pathol; 2002 Jul; 15(7):750-8. PubMed ID: 12118113
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas.
Bairey O; Zimra Y; Shaklai M; Okon E; Rabizadeh E
Clin Cancer Res; 1999 Oct; 5(10):2860-6. PubMed ID: 10537354
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
[TBL] [Abstract][Full Text] [Related]
16. p27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome.
Sáez A; Sánchez E; Sánchez-Beato M; Cruz MA; Chacón I; Muñoz E; Camacho FI; Martínez-Montero JC; Mollejo M; García JF; Piris MA
Br J Cancer; 1999 Jul; 80(9):1427-34. PubMed ID: 10424746
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.
Filipits M; Jaeger U; Pohl G; Stranzl T; Simonitsch I; Kaider A; Skrabs C; Pirker R
Clin Cancer Res; 2002 Mar; 8(3):729-33. PubMed ID: 11895902
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
